posted
The court case is coming to trial soon, and HTDS should win...
New cancer treatment from South Korea - also helps other drugs be more effective:
Historical info: TUBERCIN
Over the past ten years, epoch making anticancer agents have continuously been introduced, but the mortality of cancer patients have been rising in the U.S. and the European countries not to mention Japan and Korea. The decisive measure to cope with cancer is surgery.
When the cancer cells spread throughout the body instead of remaining on the original spot, the treatment should take into consideration chemotherapy, radiation therapy and immunotherapy. The drawback of such therapies, however, is they incur damages not only on cancer cells, but also on the normal cells.
Chemotherapy and radiation therapy are not suitable for application on weakened patients, especially those above 70. Historically, various forms of immunotherapy have been performed, falling short of therapeutic expectation. When Bacille calmetteguerin is used as an active no-specific immunotherapeutic agent, however, the patient's prognosis turns better through a simulative action on immune system of the cancer case.
Professor T.H. Chung of Korea extracted carbohydrate complex Tubercin from microbacterium tuberculosis to be used as immunostimulant. This was meant to activate the T-lymphocyte of the cancer patient to produce lymphokine. This process strengthened and promoted immuno surveillance activities in deficient state and alleviated the pain and prolonged the life of cancer patients.
Of late the pharmaceutical industry in advanced countries started to put on the market so called cancer vaccines (active specific immunotherapy). The vaccines, bacterial extracts, as adjuvants, with autologous and or allogenic cancer cells to generate antibodies to cancer cells, facilitating the killer T-cells to recognize and destroy cancer cells.
The laboratory work to modify autologous or allogenic cancer cells are not ordinary and simple. When our lab work augments the active specific immunotherapeutic agents, the Tubercin will be one of the best adjuvants. Meanwhile, the main point of AIDS is its virus killing T-cells and Tubercin helps maintain healthy T-cells. Consequently, we focus our effort on the application of Tubercin to AIDS.
TUBERCIN is derived from micro bacterium tuberculosis. As an immunostimulant, TUBERCIN strengthens the human body's own immune system and assists the body in seeking out and combating cancer cells. HTTD is potentially able to develop TUBERCIN into a low-cost product to treat cancer patients on an international scale. Salient treatment, through the administration of TUBERCIN, could positively affect thousands of lives in North America. In addition, Europe and Asia have millions of lives at risk each year because of viral diseases such as cancer.
TUBERCIN IS A FINISHED PRODUCT. Tubercin as an inmunostimulant has been administered to human patients in stages three and four of terminal cancer. There have been no indications of any adverse side effects in human trials There has been encouraging results of patients with TUBERCIN in the last fourteen years. Various forms of cancer were involved and many of the patients survived.
A review of clinical studies indicate TUBERCIN has no side effects and could possibly be administered in conjunction with other such modalities for the treatment of cancer without any adverse effects. The scientific presumption would be the distinct possibility of a strengthened immunity system and the administration of treatment such as chemotherapy at the later stages of tumor growth would not be impeded by the weakened condition of the terminal cancer patient. To this end the Company has been assisted by outside consultants reviewing the research data and human trials involving TUBERCIN to see specifically whereby incidents of dual treatment produced favorable results in terms of moving toward indication of prolongation of the life of the cancer patient.
There is recognition that morphine is an trusted pain killer, but in totality it cannot be said that it has no side effects. In the maintaining of patient care, there is the strong possibility that TUBERCIN could be also considered as a candidate for a pain management. The Company's scientists describe TUBERCIN as having the high propensity of deadening the nerve endings in specific areas of the body where cancer has caused erosion and consequently much pain.
PATENTS
Presently, HTTD has the patent rights for Korea, Japan and the United States. The Korean patent was issued on October 29, 1998 (Registration No. 173362). The Japanese patent was issued on June 12, 1998 (Registration No. 2790447). The United States patent was issued on August 14, 2001 (Registration No.6,274,356). Currently, patents are pending for Canada and Europe (the United Kingdom, France, Germany, Italy and Spain).
CANCER IN OUR TIME
In the 20th century, the number of cancer patients has been on the increase. Although many anti-cancer agents were developed and an enormous study on its essence continued, the mortality by cancer still is increasing. Mankind may be chronically threatened with cancer in the 21st century. Nine million new case of cancer occur annually and five million people die from breast cancer, reports the World Health Organization. Dramatic increases in life expectancy and change in lifestyle are estimated to increase the number of new cancer cases to 20 million annually by 2020 and cancer deaths to more than 10 million.
About 552,200 Americans - more than 1,500 people a day - are excepted to die of cancer this year. In the United States, one of every four deaths is attributed to cancer. Cancer is the second-leading cause of death in the United States. Exceeded only by heart disease. About 5 million lives have been lost to cancer since 1990 and about 13 million new cases have been diagnosed. In 2000, more then 1.2 million new cancer cases are expected to be diagnosed. The number of cancer cases will continue to grow, spurred by the aging population. By 2009, this patient group could total 8.4 million. In 1997, about 6.3 million people worldwide died from some form of cancer, and most major international cancer agencies expect this number to double by 2022.
posted
News: Hard To Treat Diseases, Incorporated Announces Trial Date - 5/19/2005 12:03:40 PM
DELRAY BEACH, Fla., May 19, 2005 (PRIMEZONE via COMTEX) -- Hard To Treat Diseases, Incorporated (HTTD) (Pink Sheets:HTDS) announces today that the Company's trial will commence on Wednesday, May 25th, at 9:30 a.m. in courtroom 205C of the U.S. Courthouse in Fort Lauderdale.
You can monitor the trial's status and the Court's calendar by signing onto the website: www.flsd.uscourts.gov and clicking on "Honorable Daniel T. K. Hurley". HTTD's case is Hard to Treat Diseases, Inc. v. Shinn, 04-80010. This trial is open to the public. As the Court's website states, "Suggested start-up dates are advisory only. Due to settlements and other reasons, the Court reserves the right to call cases for trial earlier than the listed date and out of turn."
It has come to the attention of HTTD that unrelated third-party individuals or entities are releasing information about the Company through fax and/or email blasts and that specific individuals and/or shareholders are misrepresenting the Company and its management. The Company is moving ahead with the goals described in our web site's Corporate Overview. The Company urges all investors and potential investors to review the Company's press releases and web site rather than relying on non-Company disseminated information. Our new web site is nearly complete and will be available before June 1st.
Management's intention and goal with this litigation has been to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD's shareholders and investors will be kept informed of all public developments as they occur regarding the above matters. In order to ensure the confidentiality of the Company's business and legal strategies, certain specific information may not be immediately available. Once such information can be revealed, it will be publicly disclosed to all shareholders.
HTTD is currently involved in litigation regarding the rights to Tubercin(r). Additional information and details regarding the litigation can be viewed at our website at: www.htdsotc.com
SOURCE: Hard to Treat Diseases, Inc. Hard to Treat Diseases, Incorporated Colm J. King, CEO (561) 278-7856 www.htdsotc.com .
IP: Logged |
posted
DECISION RENDERED: Hard to Treat Diseases, Inc. v. Shinn et al., 04-800010. The court has entered a memorandum opinion with findings of fact and conclusions of law holding that (1) the parties' share exchange agreement did close, (2) a Hawaiian corporation known as Shinn Capital owns the right to market a product called Tubercin, and (3) a Florida corporation known as Hard to Treat Diseases, Inc. (Florida) owns 100% of the assets of two Oklahoma corporations: Hard to Treat Diseases, Inc. (Oklahoma) and T-19, Inc. and, therefore, the Florida corporation is entitled to a money judgment against Dr. Ronald Shinn in the sum of $201,620.01. Copies of the court's opinion may be obtained from the clerk of court.
posted
to me and probably alot of other investors it looks like they lost...i read it like (1) they did close there aggreement (2) shinn ownes the right to market tubercin (3) a florida corp ownes two companies (hard to treat diseases)and (T-19 inc.) i think the money judgement was when shinn ran the operation, and miss using funds, imo iam not an attorney,
IP: Logged |
posted
I know the loss of Tubercin for the company caused the big downfall, but on the TA side the stock was overbought (RSI at or over 70 until July 5) and the 1 year chart showed anytime the RSI went over 70 the price soon fell and two bearish engulfing candles on June 30 and July 5. However it is rather easy to Monday morning quarterback and I am truly sorry to any of you who lost on this one.
IP: Logged |
posted
Hard To Treat Diseases, Incorporated Announces Company's Immediate Plans Friday July 15, 3:05 pm ET
DELRAY BEACH, Fla., July 15, 2005 (PRIMEZONE) -- Hard To Treat Diseases, Incorporated (HTTD) (Other OTC:HTDS.PK - News) announces today that the Company is preparing the appropriate legal response to the Federal Court's opinion. It is now the Company's policy to post the legal response to the Court's Memorandum Opinion on our website as soon as it is filed with the Court. Shareholders and investors will be notified by press release.
Complete copies of the Court's Memorandum Opinion and Court Transcripts can be viewed on the Company's website at: http://www.htdsotc.com Click on Corporate, then click on Legal.
ADVERTISEMENT
Management's intention and goal with this litigation has been to resolve the current dispute in the most efficient and economical manner to provide the maximum benefit to the Company and to HTTD's shareholders.
HTTD's CEO, Colm J. King, states, ``The battle is not over! HTTD has assets and will continue as a Company defending its shareholder's rights. The Company's business strategy and plans will be released after the Court's ruling regarding HTTD's legal response. HTTD fully intends to become a respected biotech with the intense focus of negotiating a deal with a major biotech/drug company and attaining the goals of benefiting patients and HTTD's shareholders, the real owners of the Company.''
-------------------- It is always darkest before it goes completely BLACK!!!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
